Compare Procter & Gamble Co (PG) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Procter & Gamble Co vs 22nd Century Group Inc — how do they compare? Procter & Gamble Co trades at $149.49 (market cap $344.87B), while 22nd Century Group Inc trades at $4.26 (market cap $1.56M). The key difference: Procter & Gamble Co is far larger — about 221070.5× 22nd Century Group Inc's market cap, and Procter & Gamble Co pays a 2.94% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals.
| PG | XXII | |
|---|---|---|
Market Cap | $344.87B | $1.56M |
Volume | 6,423,436 | — |
Sector | Consumer Staples | Technology |
52-Week High | $167.18 | $999.00 |
52-Week Low | $138.10 | $3.90 |
Enterprise Value | $370.34B | -$6.67M |
Dividend Yield | 2.94% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Procter & Gamble (PG) trades at $149.15, showing minimal daily movement with a neutral technical stance. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.59 versus $1.56 expected, and robust profitability metrics like a 50.33% gross margin. Recent developments include a multi-year WNBA partnership and ongoing dividend payments of $1.09 per share, supporting its defensive appeal amid market volatility.
PG offers stability with a 53.85% analyst buy rating and $160.50 consensus target, but premium valuations (P/E 21.65) and modest growth outlook pose near-term risks. Supply chain efficiencies and brand strength underpin resilience, though inflation and competitive pressures require monitoring for sustained shareholder returns.
XXII trades at $4.32, down 0.23% on the day, with neutral technical signals and bearish moving averages. The company shows significant financial challenges with negative profit margins (-65.76% net income margin) and declining revenue, though analyst sentiment remains positive with 75% buy ratings. Recent corporate actions include a 20:1 reverse stock split completed in June 2026, while expansion initiatives in California and New York aim to drive VLN brand growth.
The outlook remains speculative with high execution risk given persistent losses and negative ROE (-130.19%). Investment opportunity hinges on successful commercialization of reduced-nicotine products and FDA regulatory progress, but substantial financial deterioration and competitive pressures present significant downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
